Skip to content

Use of Loteprednol for Contact Lens Intolerance and Dryness

Use of Loteprednol for Contact Lens Intolerance and Dryness

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00817557
Enrollment
25
Registered
2009-01-06
Start date
2009-01-31
Completion date
2009-09-30
Last updated
2009-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contact Lenses Dryness

Keywords

Contact lenses, Loteprednol, Effect on CL dryness

Brief summary

Study of the effects of Loteprednol on CL dryness

Interventions

Anti-inflammatory

OTHERRewetter

Sponsors

Bausch & Lomb Incorporated
CollaboratorINDUSTRY
Hom, Milton M., OD, FAAO
Lead SponsorINDIV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Between the ages of 18 and over inclusive. 2. Males or females 3. Any race or ethnic background 4. CL history- experienced intolerance and either switched solutions or lenses without satisfactory relief. 5. Patient is in generally good & stable overall health. 6. Patient likely to comply with study guidelines & study visits. 7. Informed consent signed. 8. OSDI score 18 or higher while wearing lenses 9. Unsatisfactory wearing time with contact lenses

Exclusion criteria

1. Corneal refractive surgery within 6 months of this study. 2. Contact lens use on day of examination. 3. Corneal ectasia. 4. Current use of Restasis 5. Intra-ocular surgery within 6 months or ocular laser surgery within 6 months. 6. Pregnant or lactating women. 7. Ocular pathology (includes glaucoma and cataract) which could impact results and/or place patient at risk.

Design outcomes

Primary

MeasureTime frame
Wearing time28 days

Secondary

MeasureTime frame
OSDI28 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026